MannKind Is Poised To Turn A Profit And Shares Could Get Cheaper (NASDAQ:MNKD)

MannKind's bright future sets it apart from many in the disappointing biotech industry. See why MNKD stock offers growth potential, but also a considerable risk.

Related Keywords

California ,United States ,Westlake Village ,Eli Lilly ,Dragoljub Bankovic ,Zealand Pharma ,United Therapeutics Corporation ,Nasdaq ,Mannkind Corporation ,Portfolio Of Mannkind Corporation ,Medtronic ,Role Of Mannkind Corporation ,International Diabetes Federation ,Kind Corporation ,Third Quarter ,Quarterly Gross Profit Margins ,Abbott Laboratories ,Wall Street ,Strong Buy ,Teams Description ,